A Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy

Summary

The purpose of this study is to evaluate the antihypertensive efficacy and safety of Fimasartan/Hydrochlorothiazide combination 60/12.5mg\~120/12.5mg in patients with essential hypertension who are not controlled by fimasartan 60mg.

Conditions

• Essential Hypertension

Interventions

DRUG

Fimasartan/HCTZ combination

Fimasartan/HCTZ combination 60/12.5mg 120/12.5mg

DRUG

Fimasartan

Fimasartan 60mg, 120mg

Sponsors & Collaborators

• Seoul National University Hospital

  collaborator OTHER

• The Catholic University of Korea

  collaborator OTHER

• Korea University Guro Hospital

  collaborator OTHER

• DongGuk University

  collaborator OTHER

• Seoul National University Bundang Hospital

  collaborator OTHER

• Samsung Medical Center

  collaborator OTHER

• Asan Medical Center

  collaborator OTHER

• Gangnam Severance Hospital

  collaborator OTHER

• Severance Hospital

  collaborator OTHER

• Ajou University

  collaborator OTHER

• Chonbuk National University Hospital

  collaborator OTHER

• Cheil General Hospital and Women's Healthcare Center

  collaborator OTHER

• Chonnam National University Hospital

  collaborator OTHER

• Hanyang University

  collaborator OTHER

• Yonsei University

  collaborator OTHER

• Ilsan-Paik Hospital

  collaborator UNKNOWN

• SMG-SNU Boramae Medical Center

  collaborator OTHER

• Kyung Hee University Hospital

  collaborator OTHER

• Boryung Pharmaceutical Co., Ltd

  lead INDUSTRY

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2010-11-30

Primary Completion

2011-12-31

Countries

• South Korea